肝内胆管细胞癌诊治进展

Advances in diagnosis and treatment of intrahepatic cholangiocarcinoma

肝内胆管细胞癌(ICC)是发病率仅次于肝细胞癌的肝脏恶性肿瘤,它的恶性程度高、术后易复发,且早期无典型症状,大多数患者在确诊时已处于晚期。诊断主要依赖于增强CT、MRI和实验室检查。肝切除术是ICC首选的治疗方法,完整的切缘阴性切除和保留足够残留肝是影响手术预后的重要因素。淋巴结清扫、卡培他滨辅助化疗已被证实对患者有益。局部治疗、分子靶向治疗、免疫治疗等新疗法发展迅速,为晚期ICC患者带来了希望。传统疗法与新疗法的结合为ICC提供新的诊疗思路。

Intrahepatic cholangiocarcinoma(ICC)is the second most common liver malignancy after hepatocellular carcinoma.It is highly malignant,easy to recur after surgery,and has no typical symptoms in the early stage,and most patients are in the late stage when diagnosed.Diagnosis relies on enhanced CT,MRI and laboratory tests.Hepatectomy is the preferred treatment for intrahepatic cholangiocarcinoma.Complete resection with negative margin and adequate residual liver preservation are important factors affecting the prognosis of the operation.Lymph node dissection and adjuvant chemotherapy with capecitabine have been shown to be beneficial for patients.The rapid development of new therapies such as local therapy,molecular targeted therapy and immunotherapy has brought hope to patients with advanced intrahepatic cholangiocarcinoma.The combination of traditional therapy and new therapy provide a new idea for diagnosis and treatment of intrahepatic cholangiocarcinoma.